The team of Emeriti Bio has many years of experience in the field of homeostasis and fibrinolysis. The plasminogen binding inhibitor EP0003 is currently developed by Emeriti Pharma for treatment of dermatological conditions. Emeriti Bio focus on two projects outside dermatology:
- Novel fibrinolysis inhibitor for intravenous use
- Treatment of heavy menstrual bleeding
Also, Emeriti Bio has a collaboration with Vicore Pharma AB. They are developing the compound C21 for the treatment of i.a. idiopathic pulmonary fibrosis (IPF). Clinical trials are on-going. C21 is an angiotensin 2 receptor agonist. In the collaboration Emeriti Bio has synthesized new compounds related to C21.